Audentes Therapeutics, Inc.

Home » Audentes Therapeutics, Inc.

Secondary

Audentes Therapeutics, Inc.

They are a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.

Symbol

BOLD

Last Closing Price
$35.46

Shares
4,099,999

Effective Date
January 25, 2018

Underwriters
BofA Merrill Lynch, Cowen & Co., Leerink

To view the prospectus for Audentes Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253